INOVIO PHARMACEUTICALS, INC. 8-K

What Happened

• Inovio Pharmaceuticals, Inc. filed Form 8-K on May 13, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release announcing those results as Exhibit 99.1 to the filing. The filing also includes an interactive XBRL cover page as Exhibit 104.

Key Details

• Filing date: May 13, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Quarter covered: Quarter ended March 31, 2026.
• Press release: Provided as Exhibit 99.1 and incorporated by reference in the 8-K.
• Interactive data: Cover Page Interactive Data File provided as Exhibit 104 (inline XBRL).

Why It Matters

• This 8-K signals Inovio has publicly disclosed its quarterly financial results; investors should read the Exhibit 99.1 press release for the specific revenue, expense, net loss/profit, and operational metrics.
• Timely disclosure of quarterly results can affect market sentiment and the stock price; the 8-K itself does not add new terms or management changes beyond the results announcement.
• Retail investors should review the press release and any accompanying investor materials or the company’s earnings call (if scheduled) to assess financial performance and implications for their holdings.